NCT06990698View on ClinicalTrials.gov

A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

September 30, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

FP008 for injection

FP008 should be administered intravenous weekly. Six FP008 dose levels are planned to evaluated.

Trial Locations (3)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

430014

RECRUITING

Hubei Cancer Hospital, Wuhan

030013

RECRUITING

Shanxi Cancer Hospital, Taiyuan

All Listed Sponsors
lead

Zhuhai Fapon Biopharma Co., Ltd.

INDUSTRY